Literature DB >> 6373222

Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

C e Eiriksson, R N Brogden.   

Abstract

Lorcainide is a type I antiarrhythmic drug of the local anesthetic type. It can be given either intravenously or orally, and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. A slowly eliminated metabolite, norlorcainide, probably contributes to the effects of orally administered lorcainide in chronically treated patients. In mainly short term studies, lorcainide has been shown to suppress ventricular ectopy in about 80% of patients treated either orally or intravenously. Preliminary evidence suggests that its efficacy in suppressing ectopy in the setting of acute myocardial infarction is comparable with that of lignocaine (lidocaine). It is of variable efficacy in preventing recurrent ventricular tachycardia and has been shown to be effective in some patients who have failed to respond to other antiarrhythmic drugs. Experience is limited in treating supraventricular arrhythmia, but initial results in patients with Wolff-Parkinson-White syndrome have been favourable. Adverse cardiac effects are infrequent. Abnormal sinus node function may be exacerbated by lorcainide treatment, however, and bundle branch block may be precipitated in patients with pre-existing conduction system disease. Exacerbation of pre-existing arrhythmias is uncommon, and clinically important myocardial depression has not been observed. The most frequent side effect is disturbed sleep during the initiation of oral treatment, which may occur in the majority of patients but usually responds to treatment with a benzodiazepine and subsides with time. Thus, lorcainide appears useful against a variety of arrhythmias. With its convenient dosage schedule and apparently low incidence of serious side effects it should become a useful addition to the antiarrhythmic agents available, although longer term studies are needed to confirm its continued efficacy and lack of unexpected side effects when used for long periods.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6373222     DOI: 10.2165/00003495-198427040-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

1.  Clinical and electrophysiologic effects of chronic lorcainide therapy in refractory ventricular tachycardia.

Authors:  S Saksena; S T Rothbart; G Cappello; A Bernstein; P Somani
Journal:  J Am Coll Cardiol       Date:  1983-09       Impact factor: 24.094

2.  Electrophysiological effects of lorcainide in sinoatrial disease and in Wolff-Parkinson-White syndrome.

Authors:  M Manz; G Steinbeck; B Lüderitz
Journal:  Eur Heart J       Date:  1982-02       Impact factor: 29.983

3.  Electrophysiological effects of a new antiarrhythmic agent, lorcainide, on the isolated cardiac muscle fiber as compared with disopyramide.

Authors:  K Shigenobu; H Atoda; T Asano; Y Kasuya
Journal:  J Pharmacobiodyn       Date:  1980-12

4.  Alterations in the disposition of differently cleared drugs in patients with cirrhosis.

Authors:  U Klotz; C Fischer; P Müller-Seydlitz; J Schulz; W A Müller
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

5.  Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders.

Authors:  P Somani
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

6.  Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease.

Authors:  T Meinertz; F Kersting; W Kasper; H Just; H Bechtold; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

7.  Recurrent sustained ventricular tachycardia 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens.

Authors:  L N Horowitz; M E Josephson; A Farshidi; S R Spielman; E L Michelson; A M Greenspan
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

8.  Evaluation of lorcainide, a new anti-arrhythmic agent.

Authors:  E A Lloyd; L J Workman; P J Commerford; T A Mabin
Journal:  S Afr Med J       Date:  1981-12-12

Review 9.  Lorcainide (R 15 889), a first review.

Authors:  W K Amery; J J Heykants; R Xhonneux; G Towse; P Oettel; D A Gough; P A Janssen
Journal:  Acta Cardiol       Date:  1981       Impact factor: 1.718

10.  Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.

Authors:  E Carmeliet; P A Janssen; R Marsboom; J M Van Nueten; R Xhonneux
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-01
View more
  2 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Drug interaction between lorcainide and rifampicin.

Authors:  V F Mauro; P Somani; P N Temesy-Armos
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.